Table 3.

 Risk factors for AVN in a cohort of surviving SARS patients

Risk factor	Odds ratio	Confidence interval (95%)	P‐value
Age (10 years)	1.40	0.84–2.35	0.20
Sex (female)	1.02	0.40–2.65	0.96
Prednisolone‐equivalent total dose (1000 mg)*	1.42	1.14–1.77	<0.01
Maximal daily dose (100 mg)	2.22	1.44–3.41	<0.01
Duration of treatment (weeks)	1.59	1.16–2.18	<0.01
Lg10 antibody titre†	2.51	0.96–6.60	0.06
Hospital*
Hospital 1 (n = 5)	0.58	0.06–5.81	0.64
Hospital 2 (n = 17)	3.29	0.97–11.11	0.06
Hospital 3 (n = 16)	3.83	1.09–13.45	0.04
Hospital 4 (n = 33)	1.0	(Reference category)

*In a multivariate analysis of all factors with P < 0.1, only ‘prednisolone‐equivalent total dose’ remained statistically significant. In a model with ‘prednisolone‐equivalent total dose’ and ‘hospital’, the overall significance of ‘hospital’ becomes P = 0.70.

†The antibody titre was not measured for eight persons.